Randomized Controlled Trial of Renal Denervation for Resistant Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 254 participants.

Also called NCT02900729

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 254 participants (planned count) (from the registry)
Sponsor
Shanghai WiseGain Medical Devices Co., Ltd. (from the registry)
Registry
  • NCT NCT02900729
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02900729. Randomized; no masking; primary purpose treatment. Start 2016-10 (registry gives no type); primary completion 2017-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Controlled Trial of Renal Denervation for Resistant Hypertension
Condition
Hypertension
Intervention (Device)
Radiofrequency ablation catheter
Intervention (Drug)
Amlodipine, losartan potassium and hydrochlorothiazide
Lead sponsor
Shanghai WiseGain Medical Devices Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02900729
Content hash
9ab2895012b9a18c5154d3c3c2da0dd35eb50029c1c76292f612d81d4e3d7348